1-DNJ的改善性低血糖效应通过结构衍生,然后通过组装成化纳米纤维
Shuxian Ruan1, Yanli Du2, Xianyuan Zhang3
1Department of Pharmaceutics, College of Pharmacy, Jinan University, Guangzhou, People's Republic of China.
International journal of nanomedicine
|April 15, 2025
概括
对1-Deoxynojirimycin (1-DNJ) 的结构修改及其制成化纳米纤维的配方提高了其生物可用性,并延长了其降血糖效果,为糖尿病管理提供了有前途的纳米药物.
科学领域:
- 药理学和纳米医学的研究.
- 药物输送系统 药物输送系统
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 1-Deoxynojirimycin (1-DNJ) 是一种天然化合物,通过抑制α-glycosidase,有可能降低血糖.
- 它的治疗疗效受到短半衰期和体内居住时间差的限制.
- 优化1-DNJ的药理动力学特性对于有效的糖尿病管理至关重要.
研究的目的:
- 在结构上优化1-Deoxynojirimycin (1-DNJ).
- 开发一种纳米配方,以改善药理动力学特性和治疗效果.
- 为了增强1-DNJ.的口服输送和体内居住时间.
主要方法:
- N-oleoyl-1-DNJ (N-1-DNJ) 的合成.
- 使用薄膜水化和现场减少,将N-1-DNJ制成化纳米纤维 (N-1-DNJ-Se@NVs).
- 在GK大鼠体内药理动力学和低血糖性研究.
主要成果:
- 与非化配方相比,N-1-DNJ-Se@NVs表现出增强的生理稳定性和持续的药物释放.
- 药理动力学研究表明,N-1-DNJ-Se@NVs的吸收时间延长,平均保留时间增加,AUC更大,这表明其生物可用性更好.
- 这些纳米微粒表现出持久的低血糖效应,并提高了细胞吸收效率.
结论:
- 1-DNJ的结构衍生改善了它的口服输送.
- 化纳米微粒显著延长了1-DNJ的治疗效果.
- N-1-DNJ-Se@NVs代表了治疗糖尿病的有前途的纳米药物.
相关概念视频
01:05Insulin Secretory Vesicles
4.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K
01:25Insulin: Biosynthesis, Chemistry, and Preparation
320
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
320
01:23Dipeptidyl Peptidase 4 Inhibitors
134
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
134
01:24Glucagon-like Receptor Agonists
270
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
270
01:06Oral Hypoglycemic Agents: Glinides
111
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
111